Paul J Kurtin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8343219/publications.pdf

Version: 2024-02-01

64 1,575 papers citations

21 h-index 38 g-index

64 all docs 64 docs citations 64 times ranked 1938 citing authors

#	Article	IF	CITATIONS
1	Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haematologica, 2014, 99, 1239-1247.	3.5	140
2	The (11;14)(q13;q32) Translocation in Multiple Myeloma. American Journal of Clinical Pathology, 2000, 113, 831-837.	0.7	111
3	DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis. Kidney International Reports, 2018, 3, 56-64.	0.8	109
4	Amyloid Typing by Mass Spectrometry in Clinical Practice: a Comprehensive Review of 16,175 Samples. Mayo Clinic Proceedings, 2020, 95, 1852-1864.	3.0	105
5	Hematologic Characteristics of Proliferative Glomerulonephritides With Nonorganized Monoclonal Immunoglobulin Deposits. Mayo Clinic Proceedings, 2015, 90, 587-596.	3.0	92
6	An Unusual Case of Leukemic Mantle Cell Lymphoma With a Blastoid Component Showing Loss of CD5 and Aberrant Expression of CD10. American Journal of Clinical Pathology, 2004, 122, 122-127.	0.7	67
7	Shotgunâ€proteomicsâ€based clinical testing for diagnosis and classification of amyloidosis. Journal of Mass Spectrometry, 2013, 48, 1067-1077.	1.6	62
8	Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis. Nephrology Dialysis Transplantation, 2017, 32, i139-i145.	0.7	59
9	Congophilic Fibrillary Glomerulonephritis: A Case Series. American Journal of Kidney Diseases, 2018, 72, 325-336.	1.9	55
10	Inferior survival in high-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements is not associated with <i>MYC/IG</i> gene rearrangements. Haematologica, 2018, 103, 1899-1907.	3. 5	52
11	Proteomic Detection of Immunoglobulin Light Chain Variable Region Peptides from Amyloidosis Patient Biopsies. Journal of Proteome Research, 2015, 14, 1957-1967.	3.7	50
12	Correlation of histomorphological pattern of cardiac amyloid deposition with amyloid type: a histological and proteomic analysis of 108 cases. Histopathology, 2016, 68, 648-656.	2.9	48
13	Clinical, biopsy, and mass spectrometry characteristics of renal apolipoprotein A-IVÂamyloidosis. Kidney International, 2016, 90, 658-664.	5.2	42
14	Personalized risk prediction for eventâ€free survival at 24 months in patients with diffuse large Bâ€cell lymphoma. American Journal of Hematology, 2016, 91, 179-184.	4.1	41
15	Leukocyte chemotactic factor 2 amyloidosis (ALECT2) is a common form of renal amyloidosis among Egyptians. Modern Pathology, 2016, 29, 416-420.	5.5	41
16	Clinical Proteome Informatics Workbench Detects Pathogenic Mutations in Hereditary Amyloidoses. Journal of Proteome Research, 2014, 13, 2352-2358.	3.7	40
17	Renal extramedullary hematopoiesis: interstitial and glomerular pathology. Modern Pathology, 2015, 28, 1574-1583.	5 . 5	33
18	Characterization of C3 in C3 glomerulopathy. Nephrology Dialysis Transplantation, 2017, 32, gfw290.	0.7	29

#	Article	IF	CITATIONS
19	Serum levels of DNAJB9 are elevated in fibrillaryÂglomerulonephritis patients. Kidney International, 2019, 95, 1269-1272.	5.2	26
20	Proliferative Activity in Non-Hodgkin's Lymphomas: <i>A Comparison of the Bromodeoxyuridine Labeling Index with PCNA Immunostaining and Quantitative Image Analysis</i> Clinical Pathology, 1993, 99, 668-672.	0.7	24
21	Indolent Lymphomas of Mature B Lymphocytes. Hematology/Oncology Clinics of North America, 2009, 23, 769-790.	2.2	23
22	C4 Glomerulopathy: A Disease Entity Associated WithÂC4dÂDeposition. American Journal of Kidney Diseases, 2016, 67, 949-953.	1.9	23
23	LMO2 Is a Specific Marker of T-Lymphoblastic Leukemia/Lymphoma. American Journal of Clinical Pathology, 2016, 145, 180-190.	0.7	23
24	Follicular Dendritic Cell Sarcoma With Indolent T-Lymphoblastic Proliferation Is Associated With Paraneoplastic Autoimmune Multiorgan Syndrome. American Journal of Surgical Pathology, 2018, 42, 1647-1652.	3.7	23
25	Association between spinal stenosis and wild-type ATTR amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 226-233.	3.0	23
26	High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?. Blood Cancer Journal, 2020, 10, 5.	6.2	22
27	Clinical, biopsy, and mass spectrometry findings of renal gelsolin amyloidosis. Kidney International, 2017, 91, 964-971.	5.2	21
28	Apolipoprotein CII Amyloidosis Associated With p.Lys41Thr Mutation. Kidney International Reports, 2018, 3, 1193-1201.	0.8	21
29	A Patient With Hereditary ATTR and a Novel AGel p.Ala578Pro Amyloidosis. Mayo Clinic Proceedings, 2018, 93, 1678-1682.	3.0	18
30	Analysis and impact of a multidisciplinary lymphoma virtual tumor board. Leukemia and Lymphoma, 2020, 61, 3351-3359.	1.3	14
31	Proteome Of Amyloidosis: Mayo Clinic Experience In 4139 Cases. Blood, 2013, 122, 1900-1900.	1.4	13
32	Upper Gastrointestinal Bleeding from Gastric Amyloidosis in a Patient with Smoldering Multiple Myeloma. Case Reports in Gastrointestinal Medicine, 2015, 2015, 1-6.	0.3	11
33	Carboxypeptidase A1 and regenerating islet-derived $1\hat{l}_{\pm}$ as new markers for pancreatic acinar cell carcinoma. Human Pathology, 2020, 103, 120-126.	2.0	10
34	Acquired transthyretin amyloidosis after domino liver transplant: Phenotypic correlation, implication of liver retransplantation. Journal of the Neurological Sciences, 2017, 379, 192-197.	0.6	9
35	Chronic lymphocytic leukemia (CLL) with Reed–Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?. Blood Cancer Journal, 2022, 12, 18.	6.2	9
36	S-phase fraction by the labeling index as a predictive factor for progression and survival in low grade non-Hodgkin's lymphoma. Cancer, 1995, 76, 1059-1064.	4.1	7

#	Article	IF	CITATIONS
37	Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC). American Journal of Hematology, 2017, 92, 1004-1010.	4.1	7
38	Amyloidosis in surgically resected atrial appendages: a study of 345 consecutive cases with clinical implications. Modern Pathology, 2020, 33, 764-774.	5.5	7
39	The novel form of amyloidosis derived from EGFâ€containing fibulinâ€like extracellular matrix protein 1 (EFEMP1) preferentially affects the lower gastrointestinal tract of elderly females ^a . Histopathology, 2021, 78, 459-463.	2.9	7
40	Nonâ€cardiac biopsy sites with high frequency of transthyretin amyloidosis. ESC Heart Failure, 2021, 8, 750-755.	3.1	7
41	Anti-Tumor Activity of Single-Agent CCI-779 for Relapsed Mantle Cell Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group Blood, 2004, 104, 129-129.	1.4	6
42	Paraneoplastic Cast Nephropathy Associated With Pancreatic Mixed Acinar-Neuroendocrine Carcinoma: A Case Report. American Journal of Kidney Diseases, 2019, 74, 558-562.	1.9	5
43	Primary Pulmonary MALT Lymphoma: Clinical Characteristics and Treatment Outcomes – Single Institution Experience. Blood, 2010, 116, 4168-4168.	1.4	5
44	Bone marrow amyloid: a comprehensive analysis of 1,469 samples, including amyloid type, clinical features, and morphologic distribution. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 156-164.	3.0	5
45	Peripheral T-cell lymphoma involving the placenta. Cancer, 1993, 72, 300-301.	4.1	3
46	A Clinical Test for the Identification of Amyloid Proteins in Biopsy Specimens by a Novel Method Based on Laser Microdissection and Mass Spectrometry Blood, 2007, 110, 1480-1480.	1.4	3
47	Syk Tyrosine Kinase Is Overexpressed in the Majority of Peripheral T- and NK-Cell Lymphomas, and Represents a Potential Therapeutic Target Blood, 2007, 110, 690-690.	1.4	3
48	An unusual case of abnormal uterine bleeding due to classical Hodgkin lymphoma identified by endometrial biopsy. International Journal of Gynecology and Obstetrics, 2016, 135, 331-331.	2.3	2
49	First Report of Bilateral External Auditory Canal Cochlin Aggregates ("Cochlinomasâ€) with Multifocal Amyloid-Like Deposits, Associated with Sensorineural Hearing Loss and a Novel Genetic Variant in COCH Encoding Cochlin. Head and Neck Pathology, 2020, 14, 808-816.	2.6	2
50	Somatostatin-derived amyloidosis: a novel type of amyloidosis associated with well-differentiated somatostatin-producing neuroendocrine tumours. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, , 1-6.	3.0	2
51	Diagnosis and Classification of Amyloidosis in Abdominal Subcutaneous Fat Aspiration Specimens Using Mass Spectrometry Based Proteomics. Blood, 2008, 112, 2710-2710.	1.4	2
52	Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy Who Are Alive and Progression Free 12 Months After Diagnosis Have a Subsequent Overall Survival Similar to That of the General Population. Blood, 2012, 120, 1540-1540.	1.4	2
53	IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era. Blood, 2013, 122, 362-362.	1.4	2
54	Prognostic Impact of Morphology, MYC Gene Partner and BCL2/BCL6 Translocation Status in "High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements". Blood, 2016, 128, 1750-1750.	1.4	2

#	Article	IF	CITATIONS
55	Aberrant expression of lymphoid enhancer–binding factor 1 in Hodgkin lymphoma. Human Pathology, 2022, 125, 2-10.	2.0	2
56	Paraneoplastic REG1α Cast NephropathyÂAssociated With Mixed Acinar-Neuroendocrine Carcinoma. Kidney International Reports, 2021, 6, 1178-1182.	0.8	1
57	Primary Parotid MALT Lymphoma: Clinical Characteristics and Treatment – a Single Institution Experience. Blood, 2011, 118, 1580-1580.	1.4	1
58	Phase I Trial of Rituximab, Cladribine and Temsirolimus (RCT) for Initial Therapy of Mantle Cell Lymphoma. Blood, 2012, 120, 3661-3661.	1.4	1
59	Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas). Blood, 2016, 128, 155-155.	1.4	1
60	Clarifying immunoglobulin gene usage in immunoglobulin light chain amyloidosis by mass spectrometry of amyloid in clinical tissue specimens Journal of Clinical Oncology, 2014, 32, 8605-8605.	1.6	1
61	Ten Year-Old Male with Hemoglobin Lufkin/Beta-Zero Thalassemia Compound Heterozygote Who Exhibited Beta-Thalassemia Major Characteristics Blood, 2005, 106, 3815-3815.	1.4	O
62	Gene Expression Profiling of Post-Follicular B-Cell Lymphoma. Blood, 2008, 112, 617-617.	1.4	0
63	Mass Spectrometry-Based Proteomics Reveals Distinct Immunoglobulin Light Chain Variable Region Usage In Systemic Versus Localized AL Amyloidosis. Blood, 2013, 122, 3142-3142.	1.4	O
64	Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and <i>DUSP22</i> rearrangements in Anaplastic Large Cell Lymphoma. Blood, 2020, 136, 22-23.	1.4	O